Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Biosimilar pharmaceuticals 

Collaboration boosts uptake of biosimilars in gastroenterology

Researchers report that a gain-share agreement between a trust and local CCGs enhanced uptake of biosimilar infliximab CT-P13.

Xray of irritable bowel syndrome. The EMA has granted licences to several biosimilar versions of Remicade (originator infliximab) adding inflammatory bowel disease (IBD) as an indication

Source: Sovereign, ISM / Science Photo Library

Researchers found that ensuring all stakeholders are incentivised via a gain-share agreement can enhance uptake of biosimilars and generate savings for reinvestment in local gastroenterology services.

The European Medicines Agency, which evaluates medicinal products for use in Europe, has granted licences to several biosimilar versions of Remicade (originator infliximab), adding inflammatory bowel disease (IBD) as an indication. However, uptake of biosimilars is limited among gastroenterologists in the UK.

Reporting in the Journal of Crohn’s and Colitis[1] (online, 16 January 2017), researchers evaluated the outcomes of a gain-share agreement between the University Hospital Southampton NHS Foundation Trust and local clinical commissioning groups, whereby the cost savings of using biosimilars are shared equally between commissioners and secondary care providers.

The programme successfully switched 143 patients with IBD from Remicade to the biosimilar infliximab CT-P13, resulting in a reduction in drug acquisition costs of £40,000–£60,000 per month.

The team concludes that the results demonstrate that ensuring all stakeholders are incentivised via a gain-share agreement can enhance uptake of biosimilars and generate savings for reinvestment in local gastroenterology services, while maintaining similar patient-reported outcomes.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20202558

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Xray of irritable bowel syndrome. The EMA has granted licences to several biosimilar versions of Remicade (originator infliximab) adding inflammatory bowel disease (IBD) as an indication

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.